Dexamethasone News and Research

RSS

Pre-procedure medication regimen could lower incidence of hospital readmission in lung caner patients

Researchers at the University of Cincinnati College of Medicine have found that putting liver cancer patients on a medication regimen prior to undergoing a certain treatment could lead to shorter hospital stays and less chance for readmission due to complications.

10 Jun 2016

Higher blood levels of methotrexate impair executive functioning in long-term pediatric ALL survivors

Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the chemotherapy drug methotrexate are more likely to struggle with mental flexibility, organization and related skills as long-term survivors.

7 Jun 2016

Personalized DXM-loaded leukosomes may help treat inflammation

Nanosized Trojan horses created from a patient's own immune cells have successfully treated inflammation by overcoming the body's complex defense mechanisms, perhaps leading to broader applications for treating diseases characterized by inflammation, such as cancer and cardiovascular diseases.

24 May 2016

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

21 May 2016

Study evaluates effects of corticosteroids along with anti-tuberculosis drugs in tuberculous meningitis

The Cochrane Infectious Diseases Group have carried out a review update to evaluate the effects of corticosteroids being used alongside anti-tuberculosis medication to treat people suffering from tuberculous meningitis.

4 May 2016

One-dose of dexamethasone can improve outcomes of asthmatic patients in ER

Adults with asthma who were treated with one-dose dexamethasone in the emergency department had only slightly higher relapse than patients who were treated with a 5-day course of prednisone.

28 Apr 2016

Medi-551 antibody treatment decreases number of cancer stem cells by half in multiple myeloma patients

An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.

18 Apr 2016

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

PharmaMar today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM).

2 Apr 2016

Exposure to substitute chemical can stimulate formation of fat cells

Exposure to a substitute chemical often used to replace bisphenol A in plastics can encourage the formation of fat cells, according to a new study published in the Endocrine Society's journal Endocrinology.

23 Mar 2016

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

Amgen today announced that Kyprolis in combination with lenalidomide and dexamethasone is now available in the UK for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

16 Feb 2016

Simple physics may play key role in helping the body to fight infection

Simple physics may play a larger role than previously thought in helping control key bodily processes - such as how the body fights infection.

11 Feb 2016

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

A research team led by St. Jude Children's Research Hospital scientists has discovered details of how the abnormal breakage and rearrangement of chromosomes in white blood cells triggers a particularly aggressive form of acute lymphoblastic leukemia (ALL). Such leukemias are cancers of white blood cells, in which genetic mutations trigger overproduction of immature cells, called lymphoblasts.

9 Feb 2016

Palonosetron effective anti-emetic for paediatric chemotherapy patients

Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.

26 Jan 2016

Positive bosutinib response for elderly blast phase CML patient

A case study suggests that the third-generation tyrosine kinase inhibitor bosutinib may be considered as induction therapy for blast phase chronic myeloid leukaemia in older patients.

22 Jan 2016

IQWiG finds no added benefit for pomalidomide drug in multiple myeloma

Pomalidomide (trade name: Imnovid) has been approved since 2013 for the treatment of multiple myeloma that has returned and is difficult to treat. The drug is an option for adults who have received two or more prior treatment regimens, including treatment with the drugs lenalidomide and bortezomib, and in whom the last treatment had no sufficient effect.

13 Jan 2016

$Role for carfilzomib in relapsed, refractory multiple myeloma treatment$

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Carfilzomib significantly improves outcomes in previously treated patients with relapsed or refractory multiple myeloma, shows a head-to-head comparison with bortezomib.

11 Dec 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.

25 Nov 2015